FDA grants Fast Track designation to nintedanib for the treatment of sy
Fast Track designation facilitates development of new therapies that treat s...
2018-03-21
文传商讯
New England Journal of Medicine Publishes Results of Phase III FLAURA T
Tagrisso demonstrated superior progression-free survival (PFS) of 18.9 month...
2017-11-21
文传商讯
AstraZeneca and Chi-Med’s Savolitinib Shows Encouraging Clinical Activ
Data for savolitinib in combination with Tagrisso or Iressa presented at Wor...
2017-10-17
文传商讯
AstraZeneca Presents Tagrisso (osimertinib) Data in Patients with EGFR
Tagrisso extended the length of time patients with CNS metastases lived with...
2017-06-07
文传商讯
Boehringer Ingelheim Phase III study now enrolling patients with progre
For the first time, patients with different fibrosing lung diseases will be ...
2017-03-22
文传商讯
Afatinib to be evaluated in combination with PD-1 inhibitor pembrolizum
Efficacy and safety of afatinib plus pembrolizumab to be assessed in Phase I...
2017-02-10
文传商讯
Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung can
International survey showed high global EGFR testing rates prior to first-li...
2016-12-09
文传商讯
New European study highlights differing priorities in physician’s ther
Data showed that 60% of physicians prioritised factors related to maintainin...
2016-11-10
文传商讯
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic
INGELHEIM, Germany -- (BUSINESS WIRE) --Boehringer Ingelheim today announced...
2016-09-13
文传商讯
Giotrif (afatinib) approved in Europe as new oral treatment option for
Approval provides a new oral treatment option for patients with the second l...
2016-04-08
文传商讯
